Long-term observation of lung injury in children after stem cell transplants
Official title: TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Run by Children's Hospital Medical Center, Cincinnati · NCT04098445 · Data updated 2026-11-12
This study looks at children who have had stem cell transplants to see how often they develop lung problems and how these issues affect their health over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 24 Years |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 9 sites (San Francisco, California and 8 other locations) |
| Status | Recruiting |
| Started | September 8, 2021 |
| Main results expected | September 2033 |
| Study ends | September 2033 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT04098445 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 24 years or younger who are undergoing allogeneic or autologous HSCT.
✕Probably not a fit
Patients over the age of 24 will not benefit from this study as they do not meet the eligibility criteria.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) to assess the incidence and impact of pulmonary complications such as diffuse alveolar hemorrhage and bronchiolitis obliterans. It aims to fill critical knowledge gaps regarding the etiology and optimal treatment of these complications, which can significantly affect survival and quality of life. The study will involve multiple institutions and will track patients over time to improve diagnosis and treatment strategies for lung injuries associated with HSCT.
Why it matters
Potential benefit: If successful, this study could lead to better diagnosis and management of lung complications in children undergoing HSCT, ultimately improving their survival and quality of life.
How similar studies have gone: While there is ongoing research into pulmonary complications in HSCT patients, this specific longitudinal approach in a pediatric cohort is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects ≤ 24 years of age undergoing allogeneic or autologous HSCT. Exclusion Criteria: * Subjects over 24 years of age.
Where it's running
-
University of California San Francisco
San Francisco, California, United States Recruiting -
Children's Hospital Colorado
Aurora, Colorado, United States Recruiting -
Dana-Farber Cancer Institute/Boston Children's Hospital
Boston, Massachusetts, United States Recruiting -
University of Minnesota
Minneapolis, Minnesota, United States Recruiting -
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States Recruiting -
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States Recruiting
Show 3 more locations
-
Baylor College of Medicine/Texas Children'S Hospital
Houston, Texas, United States Recruiting -
Seattle Children'S Hospital
Seattle, Washington, United States Recruiting -
Fred Hutchinson Cancer Center
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Stella Davies, MBBS, PhD, MRCP — Children's Hospital Medical Center, Cincinnati
- Study coordinator: Stephanie Edwards, BSN, RN
- Email: StephanieL.Edwards@cchmc.org
- Phone: 513-636-9292
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Withaferin A to help prevent graft-versus-host disease after stem cell transplant
This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.
-
Role of Interferon and Complement in Second-ary Thrombotic Microangiopathy
This study tests whether interferon levels relate to the development of TA-TMA in people who have had a transplant or related conditions.
-
Emulsified avacopan given through a nasogastric tube for patients with ANCA-associated vasculitis and diffuse alveolar hemorrhage
This trial will try giving emulsified avacopan (30 mg twice daily) through a nasogastric tube to up to six ventilated patients with active severe GPA or MPA and diffuse alveolar hemorrhage to see how the drug is absorbed over 72 hours.
-
Venetoclax plus azacitidine consolidation vs standard chemotherapy before stem cell transplant in high-risk AML
This study tests whether a venetoclax-containing consolidation helps newly diagnosed high-risk AML patients who have CR/CRi after VA induction to improve outcomes before allo-HSCT.
-
Long-term outcomes for people with immune TTP in the French national TMA cohort
This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).
-
Observational study of blood clotting and bleeding disorders in Chinese patients
This study looks at blood clotting and bleeding problems in Chinese patients to see how common they are and what factors might affect them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.